Glenmark Pharmaceuticals stock (INE935A01035): Strong Buy rating amid profit surge

Glenmark Pharmaceuticals earned a Strong Buy rating from MarketsMojo as profits soared 890% over the past year, with latest six-month net sales up 45.83% to ?9,947 crores per data as of May 12, 2026.

Glenmark Pharmaceuticals has received a Strong Buy rating from MarketsMojo, highlighting exceptional profit growth of 890.4% over the past year, according to MarketsMojo as of May 12, 2026. The latest six-month data shows net sales reaching ?9,947.49 crores, a 45.83% increase, while profit after tax hit ?2,026.77 crores. For Q3 FY26 ending December 2025, net sales grew 15.15% year-on-year to ?3,900.62 crores despite sequential declines, per the same source.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Glenmark Pharmaceuticals Ltd
• Sector/industry: Pharmaceuticals
• Headquarters/country: India
• Core markets: Global, with focus on dermatology, respiratory and generics
• Key revenue drivers: Specialty drugs, formulations and APIs
• Home exchange/listing venue: NSE (GLENMARK)
• Trading currency: INR

Glenmark Pharmaceuticals: core business model

Glenmark Pharmaceuticals develops and markets branded and generic formulations across dermatology, respiratory, gastrointestinal and cardiovascular therapies. The company operates in over 80 countries, with a strong presence in emerging markets and the US through subsidiaries like Glenmark Pharmaceuticals Inc. Its model emphasizes R&D investment in novel molecules alongside a robust generics portfolio, as detailed on its IR site.

Revenue stems from finished dosage formulations (over 70%), active pharmaceutical ingredients and novel drug delivery systems. Glenmark holds a market cap of INR 62,822 crores as of recent quarterly data published in 2025, positioning it as a large-cap player in India's pharma sector.

Main revenue and product drivers for Glenmark Pharmaceuticals

Key drivers include global generics sales, particularly in the US where it supplies respiratory and dermatology products, and specialty brands in India and Europe. For the six months ending December 2025, net sales hit ?9,947.49 crores with 45.83% growth, and PAT at ?2,026.77 crores, according to MarketsMojo as of May 12, 2026. Q3 FY26 sales of ?3,900.62 crores showed 15.15% YoY growth, though down sequentially.

Top products feature inhalers like Galesa and skincare brands, contributing to margins improving to 22.37% in Q3 FY26 from 18.18% YoY. The company reported quarterly net sales of ?32,562 crores for Mar 2025 period, per analysis on MarketsMojo.

Industry trends and competitive position

The global pharma sector sees rising demand for generics and specialty drugs amid US pricing pressures and biosimilars growth. Glenmark competes with Sun Pharma and Cipla, outperforming with 21.44% one-year returns vs. Sensex's 9.50% as of November 17, 2025 data from MarketsMojo. Its PE ratio of 23.47 suggests undervaluation relative to peers.

Why Glenmark Pharmaceuticals matters for US investors

US investors track Glenmark via its Nasdaq-listed ADR (GLNMY) and exposure through Glenmark Pharmaceuticals Inc., which files with the SEC and supplies generics to the world's largest pharma market. Strong India-led growth provides diversification, with US sales forming a key revenue pillar amid global supply chain shifts.

Conclusion

Glenmark Pharmaceuticals shows robust financial momentum with surging sales and profits, earning a Strong Buy nod amid a recovering trajectory. While sequential fluctuations warrant monitoring, year-on-year gains and global reach underline its appeal. US investors gain exposure via ADRs to this India-based pharma contender navigating sector dynamics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.